Inflammatory bowel disease – non-biological treatment

Magro, Fernando; Cordeiro, Gonçalo; Dias, Andreia Martins; Estevinho, Maria Manuela

doi:10.1016/j.phrs.2020.105075

Cited by 77Inflammatory Bowel DiseaseOcular Diseases and Behçet’s SyndromePregnancy and Medication Impact

Inflammatory bowel disease – non-biological treatment

Magro, Fernando, Cordeiro, Gonçalo, Dias, Andreia Martins, Estevinho, Maria Manuela·2020·Pharmacological Research

DOI 10.1016/j.phrs.2020.105075

Open this paper in CoChat — free account

Abstract

Nowadays, non-biological treatments remain valuable approaches among the therapeutic armamentarium of inflammatory bowel disease (IBD). Mesalamine is the core treatment of mild‑to‑moderate ulcerative colitis (UC) and corticosteroids are crucial for the induction of remission of moderate‑to‑severe flares in both UC and Crohn's disease (CD). Even approaches as cyclosporine, tacrolimus, azathioprine, methotrexate, and surgery still have a nuclear position as strategies to induce and/or maintain remission in IBD. Due to their particularities and to the accumulated evidence, each of these strategies conquered peculiar roles in the overall IBD strategy, all of them contributing to better outcomes. This review emphasizes the particular roles that non-biological treatments gained over time: recent mesalamine formulations to increase adhesion rates, higher doses of 5-ASA for high-risk patients, MMX technology to improve drug release and attain higher bowel concentrations, cyclosporine as a bridge to vedolizumab, tacrolimus as a potential alternative to thiopurines or infliximab, azathioprine in combination therapy with infliximab and dubious in monotherapy, and surgery as a mean to a "better end".

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2020.105075

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mesalazine is a first-line agent in patients with active ulcerative colitis.
“B. dorei BDX-01 treatment was also compared with mesalazine, a first-line agent in patients with active UC (Magro et al., 2020).”
From Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway (2023) · cites this paper as Magro et al., 2020

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A. A., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,140 · see citing works
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892 · see citing works
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716 · see citing works
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., BLANK, M. A., Johanns, J., Gao, L.-L., Ye, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,851 · see citing works
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A. A., Gelernt, I. M., Bauer, J. J., Galler, G. W., Michelassi, F., & Hanauer, S. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,715 · see citing works
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,594 · see citing works
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · see citing works
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374 · see citing works
Self-citation
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268 · see citing works
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,238 · see citing works
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180 · see citing works
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J. H., Armuzzi, A., Bachmann, O. P., Bager, P., Biancone, L., Bokemeyer, B., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,107 · see citing works
Self-citation
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Panaccione, R., Ghosh, S. K., Middleton, S. J., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.052 · Cited by 973 · see citing works
European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H. A., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. J. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 931 · see citing works
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Nachury, M., Moreau, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61084-8 · Cited by 644 · see citing works
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 603 · see citing works
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A. B. R., Williams, C., Nilsson, L., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 564 · see citing works
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Yang, S., Hong, M., Baek, J., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B. D., Kim, K., Park, S. H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3060 · Cited by 549 · see citing works
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 492 · see citing works
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy.
Assche, G. V., D’Haens, G., Noman, M., Vermeire, S., Hiele, M. I., Asnong, K., Arts, J., D’Hoore, A., PENNINCKX, F. M., & Rutgeerts, P. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01214-9 · Cited by 449 · see citing works
Biomarkers of Inflammation in Inflammatory Bowel Disease
Sands, B. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.003 · Cited by 406 · see citing works
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial
Ponsioen, C. Y., de Groof, E. J., Eshuis, E. J., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30248-0 · Cited by 367 · see citing works
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
Ko, C. W., Singh, S., Feuerstein, J. D., Falck-Ytter, C., Falck-Ytter, Y. T., Cross, R. K., Crockett, S. D., Falck-Ytter, Y. T., Feuerstein, J. D., Flamm, S. L., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.12.009 · Cited by 340 · see citing works
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Feagan, B. G., McDonald, J. W., Panaccione, R., Enns, R. A., Bernstein, C. N., Ponich, T. P., Bourdages, R., MacIntosh, D. G., Dallaire, C., Cohen, A., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.11.024 · Cited by 331 · see citing works
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
Relling, M. V., Gardner, E. E., Sandborn, W. J., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.4 · Cited by 329 · see citing works
Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial
Hanauer, S. B., Sandborn, W. J., Kornbluth, A. A., Katz, S., Safdi, M. A., Woogen, S. D., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F. O. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00248.x · Cited by 320 · see citing works
Epstein-Barr virus–positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine
Dayharsh, G. A., Loftus, E. V., Sandborn, W. J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.30328 · Cited by 278 · see citing works
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
Williams, J. G., Alam, M. F., Alrubaiy, L., Arnott, I. D., Clement, C., Cohen, D. R., Gordon, J. N., Hawthorne, A. B., Hilton, M., Hutchings, H. A., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30003-6 · Cited by 271 · see citing works
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Travis, S. P. L., Danese, S., Kupčinskas, L., Alexeeva, O., D’Haens, G., Gibson, P. R., Moro, L., Jones, R., Ballard, E. D., Masure, J. A., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-304258 · Cited by 262 · see citing works
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 255 · see citing works
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
Sandborn, W. J., Travis, S. P. L., Moro, L., Jones, R., Gautille, T., Bagin, R. G., Huang, M., Yeung, P., & Ballard, E. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.003 · Cited by 245 · see citing works
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
Matsumoto, T., Motoya, S., Watanabe, K., et al. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw152 · Cited by 241 · see citing works
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis
Ogata, H., Kato, J., Hirai, F., Hida, N., Matsui, T., Matsumoto, T., Koyanagi, K., & Hibi∥, T. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21853 · Cited by 212 · see citing works
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids
Narula, N., Marshall, J. K., Colombel, J., Leontiadis, G. I., Williams, J. G., Muqtadir, Z., & Reinisch, W. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.7 · Cited by 204 · see citing works
Acute severe ulcerative colitis: from pathophysiology to clinical management
Hindryckx, P., Jairath, V., & D’Haens, G. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.116 · Cited by 193 · see citing works
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis
Löfberg, R., Danielsson, Å., Suhr, O. B., Nilsson, A., Schiöler, R., Nyberg, A. H., Hultcrantz, R., Kollberg, B., Gillberg, R., Wïllén, R., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8964395 · Cited by 188 · see citing works
Crohn’s Disease Patients’ Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy
Johnson, F. R., Özdemir, S., Mansfield, C. A., Hass, S., Miller, D. W., Siegel, C. A., & Sands, B. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.075 · Cited by 187 · see citing works
Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitis
Peyrin‐Biroulet, L., Germain, A., Patel, A. S., & Lindsay, J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13763 · Cited by 180 · see citing works
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
Walker, G., Harrison, J., Heap, G., Voskuil, M. D., Andersen, V. C., Anderson, C. A., Ananthakrishnan, A. N., Barrett, J. C., Beaugerie, L., Bewshea, C., et al. (2019) · JAMA · doi:10.1001/jama.2019.0709 · Cited by 171 · see citing works
Risk of liver disease in methotrexate treated patients
Conway, R., & Carey, J. J. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i26.1092 · Cited by 170 · see citing works
Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
Hanauer, S. B., Sandborn, W. J., Dallaire, C., et al. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/862917 · Cited by 165 · see citing works
Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
Yarur, A. J., Kubiliun, M. J., Czul, F., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.12.026 · Cited by 161 · see citing works
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
Lewis, J. D., Scott, F. I., Brensinger, C. M., Roy, J. A., Osterman, M. T., Mamtani, R., Bewtra, M., Chen, L., Yun, H., Xie, F., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.479 · Cited by 151 · see citing works
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology
Dubois‐Camacho, K., Ottum, P. A., Franco-Muñoz, D., la Fuente, M. D., Torres, A., Díaz-Jiménez, D., Olivares-Morales, M., Astudillo, G. E., Quera, R., & Hermoso, M. A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6628 · Cited by 145 · see citing works
Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease
Cohen, B. L., & Sachar, D. B. (2017) · BMJ · doi:10.1136/bmj.j2505 · Cited by 144 · see citing works
History of Inflammatory Bowel Diseases
Actis, G. C., Pellicano, R., Fagoonee, S., & Ribaldone, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111970 · Cited by 140 · see citing works
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial
Roblin, X., Williet, N., Boschetti, G., Phelip, J., Tedesco, É. D., Berger, A.-E., Vedrines, P., Duru, G., Peyrin‐Biroulet, L., Nancey, S., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319758 · Cited by 137 · see citing works
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial
Roblin, X., Boschetti, G., Williet, N., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14106 · Cited by 134 · see citing works
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
Lightner, A. L., Raffals, L. E., Mathis, K. L., Cima, R. R., Tse, C. S., Pembérton, J. H., Dozois, E. J., & Loftus, E. V. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw147 · Cited by 131 · see citing works
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis
Singh, S., Feuerstein, J. D., Binion, D. G., & Tremaine, W. J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.12.008 · Cited by 130 · see citing works
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
for the MENDEL study group, Kakuta, Y., Kawai, Y., Okamoto, D., Takagawa, T., Ikeya, K., Sakuraba, H., Nishida, A., Nakagawa, S., Miura, M., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1486-7 · Cited by 127 · see citing works
Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United States
Tremaine, W. J., Hanauer, S. B., Katz, S., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05835.x · Cited by 119 · see citing works
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Ooi, C. J., Hilmi, I. N., Banerjee, R., Chuah, S. W., Ng, S. C., Wei, S. C., Makharia, G. K., Pisespongsa, P., Chen, M. H., Ran, Z. H., et al. (2019) · Intestinal Research · doi:10.5217/ir.2019.00026 · Cited by 109 · see citing works
Management of Inflammatory Bowel Disease in the Elderly Patient
Ananthakrishnan, A. N., Donaldson, T., Lasch, K. L., & Yajnik, V. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001099 · Cited by 108 · see citing works
Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial
de Groof, E. J., Stevens, T. W., Eshuis, E. J., Gardenbroek, T. J., Bosmans, J. E., van Dongen, J. M., Mol, B., Buskens, C. J., Stokkers, P. C. F., Hart, A. L., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317539 · Cited by 106 · see citing works
Surgery for inflammatory bowel disease in the era of laparoscopy
Sica, G. S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i16.2445 · Cited by 103 · see citing works
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Chande, N., Townsend, C., Parker, C. E., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub5 · Cited by 103 · see citing works
Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis
Komaki, Y., Komaki, F., Ido, A., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv221 · Cited by 93 · see citing works
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
Christensen, B., Gibson, P. R., Micić, D., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.060 · Cited by 90 · see citing works
Surgery in the age of biologics
Wong, D. J., Roth, E. M., Feuerstein, J. D., & Poylin, V. Y. (2019) · Gastroenterology report · doi:10.1093/gastro/goz004 · Cited by 90 · see citing works
Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe
Burisch, J. M., Pedersen, N. K., Cukovic-Cavka, S., Turk, N., Kaimakliotis, I. P., Ďuricová, D., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000436277.13917.c4 · Cited by 88 · see citing works
Self-citation
Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients
Schmidt, K. J., Herrlinger, K. R., Emmrich, J., Barthel, D. N., Koç, H., Lehnert, H., Stange, E. F., Fellermann, K., & Büning, J. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12118 · Cited by 83 · see citing works
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Wong, U., & Cross, R. K. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1377180 · Cited by 83 · see citing works
Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis
D’Haens, G., Kovács, Á., Vergauwe, P. L., Nagy, F. T., Molnár, T., Bouhnik, Y., Weiss, W., Brünner, H., Lavergne‐Slove, A., Binelli, D., et al. (2009) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.09.007 · Cited by 81 · see citing works
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Rubin, D. T., Cohen, R. D., Sandborn, W. J., Lichtenstein, G. R., Axler, J. L., Riddell, R. H., Zhu, C., Barrett, A. C., Bortey, E. B., & Forbes, W. P. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx032 · Cited by 80 · see citing works
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis
Pellet, G., Stéfanescu, C., Carbonnel, F., Peyrin‐Biroulet, L., Roblin, X., Allimant, C., Nachury, M., Nancey, S., Filippi, J., Altwegg, R., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.081 · Cited by 79 · see citing works
Steroid dependency and trends in prescribing for inflammatory bowel disease – a 20‐year national population‐based study
CHHAYA, V. A., Saxena, S. K., Cecil, E. V., Subramanian, V., Ćurčin, V., Majeed, A., & Pollok, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13700 · Cited by 75 · see citing works
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Pagnini, C., Pizarro, T. T., & Cominelli, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00671 · Cited by 75 · see citing works
Adverse events in IBD therapy: the 2018 update
Quezada, S. M., McLean, L. P., & Cross, R. K. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1545574 · Cited by 73 · see citing works
Mucosal healing and deep remission: What does it mean?
Rogler, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i43.7552 · Cited by 72 · see citing works
Treatment of inflammatory bowel disease with corticosteroids
Katz, J. (2004) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.02.002 · Cited by 68 · see citing works
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Nguyen, N. H., Fuméry, M., Dulai, P. S., Prokop, L. J., Sandborn, W. J., Murad, M. H., & Singh, S. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30231-0 · Cited by 68 · see citing works
Anti-infliximab antibodies in inflammatory bowel disease
Lee, L. Y. W., Sanderson, J. D., & Irving, P. M. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835558cf · Cited by 65 · see citing works
Assessment of steroid use as a key performance indicator in inflammatory bowel disease—analysis of data from 2385 UK patients
Selinger, C. P., Parkes, G. C., Bassi, A., Limdi, J. K., Ludlow, H., Patel, P., Smith, M. A., Saluke, S., Ndlovu, Z., George, B., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15497 · Cited by 65 · see citing works
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease
Boyapati, R. K., Torres, J., Palmela, C., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012540.pub2 · Cited by 63 · see citing works
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial
Groß, V., Bunganič, I., Александровна, Б. Е., Mikhailova, T. L., Kupčinskas, L., Kiudelis, G., Tulassay, Z., Gabalec, L., Dorofeyev, A. E., Derova, J., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2010.11.006 · Cited by 62 · see citing works
Combination Immunosuppression in IBD
Bots, S. J., Gecse, K. B., Barclay, M. L., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx065 · Cited by 62 · see citing works
Evolving Role of IBD Surgery
Bemelman, W. A., collaborators, S.-E., Adamina, M., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy056 · Cited by 62 · see citing works
Systematic Review and Meta-analysis
Chalhoub, J. M., Rimmani, H. H., Gumaste, V. V., & Sharara, A. I. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001203 · Cited by 60 · see citing works
Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases
Chang, J. Y., Park, S. J., Jung, E. S., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.034 · Cited by 54 · see citing works
Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients
Miyoshi, J., Matsuoka, K., Inoue, N., et al. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.04.018 · Cited by 52 · see citing works
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
Prantera, C. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12473675 · Cited by 51 · see citing works
Tacrolimus for the Treatment of Ulcerative Colitis
Matsuoka, K., Saito, E., Fujii, T., et al. (2015) · Intestinal Research · doi:10.5217/ir.2015.13.3.219 · Cited by 51 · see citing works
Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis
D’Haens, G., Sandborn, W. J., Zou, G., Stitt, L., Rutgeerts, P. J., Gilgen, D., Jairath, V., Hindryckx, P., Shackelton, L. M., Vandervoort, M. K., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14164 · Cited by 48 · see citing works
Role of endoscopy in inflammatory bowel disease
Bharadwaj, S., Narula, N., Tandon, P., & Yaghoobi, M. (2018) · Gastroenterology report · doi:10.1093/gastro/goy006 · Cited by 46 · see citing works
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Endo, K., Onodera, M., Shiga, H., et al. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/3162595 · Cited by 45 · see citing works
Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Rubin, D. T., Cohen, R. D., Sandborn, W. J., Lichtenstein, G. R., Axler, J. L., Riddell, R. H., Zhu, C., Barrett, A. C., Bortey, E. B., & Forbes, W. P. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx052 · Cited by 45 · see citing works
Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease
Colman, R. J., & Rubin, D. T. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv027 · Cited by 44 · see citing works
Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era
Mantzaris, G. J. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0128-0 · Cited by 43 · see citing works
Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review
Wu, B.-Y., Tong, J., & Ran, Z. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz068 · Cited by 40 · see citing works
What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.
Dalal, S. R., & Cohen, R. D. (2015) · PubMed Central · Cited by 39 · see citing works
Combination therapy for inflammatory bowel disease
Sultan, K. S., Berkowitz, J. C., & Khan, S. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i2.103 · Cited by 37 · see citing works
Interventional IBD: The Role of Endoscopist in the Multidisciplinary Team Management of IBD
Shen, B. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx058 · Cited by 37 · see citing works
Cyclosporine for Severe Ulcerative Colitis
Pham, C. Q. D., Efros, C. B., & Berardi, R. R. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g374 · Cited by 34 · see citing works
The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry
Fukuda, T., Naganuma, M., Sugimoto, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187737 · Cited by 34 · see citing works
Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease
Lord, J. D., & Shows, D. M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i18.3240 · Cited by 31 · see citing works
Methotrexate for Inflammatory Bowel Diseases - New Developments
Herfarth, H. H. (2016) · Digestive Diseases · doi:10.1159/000443129 · Cited by 28 · see citing works
Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis
Kuehn, F., & Hodin, R. A. (2018) · Visceral Medicine · doi:10.1159/000493492 · Cited by 28 · see citing works
Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease
Rodríguez–Lago, I., Castro‐Poceiro, J., Fernandez-Clotet, A., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15687 · Cited by 25 · see citing works
Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy
van Gennep, S., Sahami, S., Buskens, C. J., BRINK, G. R. V. D., Ponsioen, C. Y., D’Hoore, A., van Overstraeten, A. D. B., Assche, G. V., Ferrante, M., Vermeire, S., et al. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000798 · Cited by 24 · see citing works
A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease
Estevinho, M. M., Afonso, J., Rosa, I., Lago, P. M., Trindade, E., Correia, L., Dias, C. C., Magro, F., & on behalf GEDII [Portuguese IBD Group] (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx089 · Cited by 24 · see citing works
Self-citation
Pharmacotherapy of ulcerative colitis – current status and emerging trends
Ahmad, H., & Kumar, V. L. (2018) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2016-0014 · Cited by 22 · see citing works
Elective Abdominal Surgery for Inflammatory Bowel Disease
Feinberg, A. E., & Valente, M. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.08.004 · Cited by 19 · see citing works
Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta‐analysis
Li, W., Zhang, Z. ‐., & Jiang, X. (2016) · Colorectal Disease · doi:10.1111/codi.13393 · Cited by 18 · see citing works
6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn’s Disease
Mao, R., Guo, J., Luber, R. P., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy173 · Cited by 18 · see citing works
Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
Verdon, C., Bessissow, T., & Lakatos, P. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122169 · Cited by 18 · see citing works
Impact of Early Surgery and Immunosuppression on Crohnʼs Disease Disabling Outcomes
Magro, F., Dias, C. C., Coelho, R., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001007 · Cited by 17 · see citing works
Self-citation
Current management of intestinal bowel disease: the role of surgery
Solina, G., Mandalà, S., Barbera, C., & Mandalà, V. (2016) · Updates in Surgery · doi:10.1007/s13304-016-0361-4 · Cited by 16 · see citing works
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild‐to‐moderate ulcerative colitis
Danese, S., Hart, A. L., Dignass, A. U., Fiorino, G., Louis, E. J., Bonovas, S., D’Haens, G., Dotan, I., Rogler, G., Paridaens, K., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619864848 · Cited by 16 · see citing works
A novel player: cyclosporine therapy in the management of inflammatory bowel disease
Weissman, S. I., Chris-Olaiya, A., Mehta, T. I., et al. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.08.08 · Cited by 16 · see citing works
Trends and Outcomes for Minimally Invasive Surgery for Inflammatory Bowel Disease
Gaglani, T., Davis, C. H., Bailey, H. R., & Cusick, M. V. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.09.075 · Cited by 15 · see citing works
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Ogata, H., Aoyama, N., Mizushima, S., Hagino, A., & Hibi∥, T. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.3.368 · Cited by 14 · see citing works
Key insights from therapeutic drug monitoring in Crohn’s disease patients
Seinen, M. L., de Boer, N. K. H., & van Bodegraven, A. A. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1597054 · Cited by 14 · see citing works
What is the real-life maintenance mesalazine dose in ulcerative colitis?
Algaba, A., Guerra, I., de Paredes, A. G. G., Tejero, M. H., Ferré, C., Bonillo, D., Aguilera, L., López–Sanromán, A., & Bermejo, F. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4620/2016 · Cited by 12 · see citing works
The Evolving Role of Thiopurines in Inflammatory Bowel Disease
Kapur, S., & Hanauer, S. B. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00244-3 · Cited by 10 · see citing works
The Evolving Role of Thiopurines for Inflammatory Bowel Disease
Rosen, D. J., & Dubinsky, M. C. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000583 · Cited by 8 · see citing works
Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
Ogata, H., Ohori, A., Nishino, H., et al. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.3.358 · Cited by 6 · see citing works
The timing of early therapeutic strategies has a significant impact on Crohn’s disease prognosis
Dias, C. C., Portela, F., Fernandes, S. R., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.01.135 · Cited by 6 · see citing works
Ulcerative colitis: management
Nice Guideline Updates Team (2019) · Cited by 6 · see citing works
The Impact of Biologic Therapy on Outcomes of Inflammatory Bowel Disease Surgery.
Loftus, E. V. (2019) · PubMed · Cited by 6 · see citing works
Should surgical intervention become a primary treatment modality in Crohn’s disease?—A review of the role of surgery and emerging surgical techniques
Connelly, T. M., Malik, Z., Sehgal, R., et al. (2018) · Mesentery and Peritoneum · doi:10.21037/map.2018.06.01 · Cited by 5 · see citing works
Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids
Wu, D., Yang, Z., Zhao, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012657 · Cited by 5 · see citing works
Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis
Zheng, X. M., Zhang, Z., Wang, B., et al. (2019) · Medicine · doi:10.1097/md.0000000000015113 · Cited by 4 · see citing works
Optimizing biologic therapy for treatment of inflammatory bowel disease.
Assche, G. V. (2013) · PubMed · Cited by 3 · see citing works
Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis
Magro, F., & Estevinho, M. M. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619878588 · Cited by 3 · see citing works
Self-citation
Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
Jeon, S. R. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.2.163 · Cited by 2 · see citing works
Evolution of Surgical Treatment of Ulcerative Colitis
Poggioli, G., Gentilini, L., Coscia, M., Boschi, L., & Ugolini, F. (2018) · Updates in surgery/Updates in surgery series · doi:10.1007/978-88-470-3977-3_7 · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway
Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205323 · Cited by 33 · see citing works
“dorei BDX-01 treatment was also compared with mesalazine, a first-line agent in patients with active UC (Magro et al., 2020).”
Result

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn’s Disease Patients with Adalimumab Non-response in the USA
Erim, D., Mahendraratnam, N., Okafor, P. N., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv090 · Cited by 12 · see citing works
SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
Bau, M., Zacharias, P., Ribeiro, D. A., et al. (2017) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201700000-43 · Cited by 16 · see citing works
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377 · see citing works
Effectiveness of infliximab after adalimumab failure in Crohn's disease.
Chaparro, M., Andreu, M. G., Acosta, M. B., et al. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5219 · Cited by 33 · see citing works
Effectiveness of infliximab after adalimumab failure in Crohn＇s disease
Fragaki, M., Chaparro, Montserrat, et al. (2012) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 26 · see citing works

Authors: Magro, F., Cordeiro, G., Dias, A. M., & Estevinho, M. M.
Affiliations: Universidade do Porto (PT)
Hospital de São João (PT)
Corresponding author: Magro, Fernando
ORCID: Magro, Fernando
Dias, Andreia Martins
Venue: Pharmacological Research
Publisher: Elsevier BV
Published: 2020-10
Volume: 160
Pages: 105075
ISSN: 1043-6618 (ISSN-L)
DOI: 10.1016/j.phrs.2020.105075
OpenAlex: W3040910387
Cited by: 77
References: 127
Citations by year: 2026: 3 · 2025: 13 · 2024: 20 · 2023: 18 · 2022: 9 · 2021: 14
FWCI: 1.47
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Pharmacological Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn's disease, 5-aminosalicylic acid, corticosteroids, cyclosporine, tacrolimus, azathioprine, methotrexate, vedolizumab, thiopurines, infliximab, IBD surgery, drug adhesion
MeSH terms: Adrenal Cortex Hormones, Anti-Inflammatory Agents, Colitis, Ulcerative, Crohn Disease, Gastrointestinal Agents, Humans, Methotrexate, Digestive System Surgical Procedures, Tacrolimus, Cyclosporine, Treatment Outcome, Mesalamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inflammatory bowel disease – non-biological treatment

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks